Goldman Sachs starts coverage for IDEXX Laboratories stock at USD 740.00
Published on 10/20/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGoldman Sachs starts coverage
- Goldman Sachs initiated coverage with a USD 740.00 target on October 16, 2026.
- Second-quarter revenue reached USD 1.22 billion, up 9.70 percent year over year.
- IDEXX Laboratories stock costs EUR 495.00 at Lang & Schwarz on October 20, 2026 at 6:50 p.m. CEST, unchanged versus the Xetra close of October 20, 2026.
IDEXX Laboratories (ISIN US45168D1046) received a new Wall Street reference point when Goldman Sachs started coverage with a Buy rating and a USD 740.00 price target on October 16, 2026, according to MarketBeat. IDEXX Laboratories stock was unchanged at EUR 495.00 at Lang & Schwarz on October 20, 2026 at 6:50 p.m. CEST versus the Xetra close of EUR 495.00 on October 20, 2026.
Goldman Sachs sets a USD 740 target
The Goldman Sachs target stands 32.87 percent above the latest Nasdaq price of USD 556.67, calculated in the same currency. The firm began coverage with a Buy rating, while the latest published analyst range included targets from USD 665.00 to USD 823.00, according to MarketBeat.
Second-quarter growth reached 9.70 percent
IDEXX reported second-quarter 2026 revenue of USD 1.22 billion, up 9.70 percent from the same quarter a year earlier. Adjusted earnings per share reached USD 4.27, compared with USD 3.94 consensus, according to MarketBeat. Operating profit was USD 425.57 million and the operating margin was 35.00 percent in that quarter.
What comes before the next results?
IDEXX is scheduled to release third-quarter 2026 results before the market opens on November 2, 2026, with its conference call set for 8:30 a.m. ET. The date was announced in an October 1, 2026 release from IDEXX Laboratories.
Valuation stays tied to execution
The stock's price-to-earnings ratio was 39.42 and market capitalization was USD 43.9 billion as of October 20, 2026. Its Nasdaq 52-week range was USD 500.61 to USD 769.98, while the German euro range was EUR 431.80 to EUR 663.20 on the same date.
Stock position after the Xetra close
IDEXX Laboratories stock stood at EUR 495.00 at Lang & Schwarz on October 20, 2026 at 6:50 p.m. CEST. The price was unchanged versus the Xetra close of EUR 495.00 dated October 20, 2026, and sat 25.39 percent below the euro 52-week high of EUR 663.20.
The further course of trading is shown by the continuously updated real-time quote of IDEXX Laboratories stock.
IDEXX Laboratories stock at a glance
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 6:50 p.m. CEST): EUR 495.00
- Change versus Xetra close: unchanged, 0.00 percent
- Xetra close (October 20, 2026): EUR 495.00
- Market capitalization: USD 43.9 billion (as of October 20, 2026)
- 52-week range: EUR 431.80-EUR 663.20 (as of October 20, 2026)
- Sector / Industry: Health care / Health care equipment
- Index membership: S&P 500
- Next earnings date: November 2, 2026
Market context: Market report S&P 500.
